Company intelligence / Profile preview
Abologix
Plan-les-Ouates / Geneva, Geneva, Switzerlandabologix.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Abologix develops monoclonal antibodies targeting novel cancer pathways. Its lead candidate, H225, blocks JAM-C and aims to treat non-Hodgkin’s lymphoma patients resistant to conventional therapies. The company also has a second antibody for colorectal and blood cancers. No published clinical results yet; pipeline appears preclinical or early-stage.
- Therapeutic areas
- OncologyHematology
- Modalities
- monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Abologix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abologix.